Categoría: Oncology & Cancer

Li-Fraumeni syndrome is a rare hereditary disease that significantly increases the risk of developing cancer. Almost all affected individuals receive a cancer diagnosis at least once in their lifetime. A new study suggests that the immune system is par…

Researchers in Class of 1942 Professor of Chemistry Matthew D. Shoulders’ lab have uncovered a sinister hidden mechanism that can allow cancer cells to survive (and, in some cases, thrive) even when hit with powerful drugs. The secret lies in a cellula…

Why do some tumors spread while others remain localized? The mechanisms governing the metastatic potential of tumor cells remain largely unknown—yet understanding this is crucial for optimizing patient care.

A new study shows that cancer damages its own DNA by pushing key genes to work too hard. Researchers found that the most powerful genetic «on switches» in cancer cells, called super-enhancers, drive unusually intense gene activity. That high gear creat…

A study led by Aaron Hobbs, Ph.D., and Rachel Burge, Ph.D., at MUSC Hollings Cancer Center, reveals why a specific gene mutation behaves differently from other variants.

A novel liquid biopsy technology is set to advance cancer diagnostics and monitoring by overcoming the long-standing challenge of simultaneously achieving high sensitivity, broad coverage, and simple workflow. A team of researchers from Genomill Health…

Data from a major U.S. clinical trial from the Alliance for Clinical Trials in Oncology has uncovered a genetic factor that may inform how to optimize the dosing of abiraterone, a widely used hormone treatment for advanced prostate cancer. Published in…

A whole-genome sequencing approach shows early promise over current commercial methods for identifying more patients likely to benefit from PARP inhibitor cancer treatments, according to a study led by Weill Cornell Medicine and NewYork-Presbyterian in…

A new study by the National Cancer Research Center (CNIO) has identified several sets of genes related to the predisposition to develop pancreatic ductal adenocarcinoma (the most common type of pancreatic cancer), as well as the prognosis of the diseas…

Mutations in the tumor suppressor TP53 are a common cause of cancer, making the altered protein an attractive target for therapeutics. Among them, the Y220C mutation is the ninth most frequent and it creates a small crevice in the mutant protein that i…